Lawyers at Osborne Clarke in Bristol have advised medical device company Creo Medical Group plc on the sale of 51 per cent of a subsidiary to Micro-Tech.

Chepstow-based Creo Medical Group has entered into a binding agreement with Micro-Tech – which manufactures endoscopic medical devices - for the sale of 51 per cent of the issued share capital of Creo Europe, a wholly owned subsidiary.

Creo Europe manufactures and distributes specialist gastroenterology, urology and endoscopy products to healthcare providers across Europe.

A multijurisdictional Osborne Clarke corporate team advised on the transaction, including Bristol-based partner David Ferris and associate director James Mackay. It also included counsel Sara Barona, partner David Miranda and associate Pilar Diaz in Spain.

Osborne Clarke has a market-leading international corporate/M&A practice, with a strong track record of providing highly sophisticated advice to both buy-side and sell-side on cutting-edge issues, across multiple service lines. The team has experience advising a varied range of clients, from global businesses to fast-growth start-ups and market challengers.